Ashley Yeo is attached to the medtech titles within Informa’s Pharma intelligence division.
As Health Care editor on In Vivo (monthly hardcopy and online daily services), he writes and commissions news and feature material to meet the strategic business and market access information needs of senior players and device makers as they move innovations into the global medtech market place.
As part of the Principal Analyst team, he also contributes news delivery and insight needs across the group’s other medtech titles in the field of market access (global regulatory, reimbursement, policy changes). Key areas of focus are Germany, the UK and global themes, and EU and other outside global regulatory insight.
A linguist by training, he joined what was later to become Informa in mid-1988 as a French and German news reporter (with some other European languages also in the mix), and has been editor of three of the group’s titles (including Clinica) over a 14-year-period.
These duties are combined with supporting the growing Ask The Analyst service. He says: “This helps us as a group keep a close relationship with long-term and potential subscribers in a sector where insight and knowledge are key to our clients’ commercial success.”
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ashley Yeo
While Zimmer Biomet's search goes on for a new CEO to replace David Dvorak, who stood down in mid-summer, analysts are pressing for a replacement in short order to put stability back into the global No.2 orthopedic device group, which has sales headwinds and ongoing implant production issues at North Campus, Warsaw, to contend with.
Germany's medtech industry is yet to find out who will hold the political reins for health care and the other ministerial portfolios that influence the market access and innovation support mechanisms for medtech products. Meanwhile, in the run-up to Medica 2017, German manufacturers were reporting both moderate business growth and increasing concern about reimbursement issues and the EU MDR and IVDR, which are making life less predictable for medtech innovators.
Too risky? Too costly? Global medtech innovators have tended to look at Japan as a market they might graduate to after cracking the US and EU. But Japan has changed in recent years and offers opportunities to medtech companies with products for unmet needs, as long as those firms are willing to commit themselves to understanding the dynamics of the market and its unique aspects.
The European industry association MedTech Europe (MTE) issued its Brexit position paper last week, in good time for the UK's article 50 negotiators to heed its warnings about the fall-out that a "hard Brexit," in which the UK emerges from the talks with no trade deal, could have on the business of health care and patient well-being, in the UK and beyond.
The UK devices and diagnostics industries were quick to react to the long-overdue government response to the fall 2016 Accelerated Access Review, a proposal to fast-track innovation into the NHS to the benefit of UK science, patients and the economy. Coinciding with Brexit, it is a fine-sounding plan, but will there be practical follow-through for medtech too?
Just as health care payment models differ from those of any other industry, so within health care do those for digital health solutions differ from all other branches. Digital providers say a fundamental change in the way care is provided and reimbursed is called for, in the knowledge that success in this market will depend on interaction with and by patients: that's not yet happening at scale, but it must, says Philips chief innovation and strategy officer Jeroen Tas.